UTMB develops a universal vaccine platform that’s cheaper and shelf stable
Researchers at The University of Texas Medical Branch at Galveston have developed a less expensive way to produce vaccines that cuts the cost of vaccine production and storage by 80 percent without decreasing safety or effectiveness. The findings are currently available in EBioMedicine.
Vaccines are the most effective way to prevent and eradicate infectious diseases. Currently, many vaccines have to be manufactured in cell culture or eggs, which is expensive and carries the risk of contaminations. In addition, most vaccines must be kept refrigerated during the transportation from manufacturers to health care clinics. In tropical and subtropical regions, such cold storage requirements could contribute to more than 80 percent of the vaccine cost.
“The ability to eliminate cell culture or eggs and cold storage will change the process of vaccine development,” said UTMB’s Pei-Yong Shi, professor in the department of biochemistry and molecular biology. “Importantly, this vaccine technology could potentially serve as a universal platform for development of live-attenuated vaccines for many viral pathogens.”
To achieve these goals, the UTMB team engineered a live-attenuated Zika vaccine in the DNA form. Once the DNA is delivered into our body, it launches the vaccine in our cells, leading to antibody production and other protective immunity. With this production method, there is no need to manufacture the vaccine in cell culture or eggs at factories. Because DNA molecules are shelf stable, the vaccine will not expire at warm temperatures and could be stockpiled at room temperature for years.
Using UTMB’s Zika vaccine as a model, the research group showed that the DNA platform worked very efficiently in mice. After a single low dose, the DNA vaccine protected mice from Zika virus infection, mother-to-fetus transmission during pregnancy and male reproductive tract infection and damage.
“This is the first study to demonstrate that, after a single low dose, a DNA vaccine could induce saturated protective immunity,” Shi said. “We will continue testing this promising Zika vaccine platform and then apply the platform to other viruses.”
The Latest on: Vaccine production
via Google News
The Latest on: Vaccine production
- Vaccines to stimulus checks: Here’s what’s in Biden planon January 17, 2021 at 6:10 pm
Using pharmacies around the country to administer the vaccine. The Trump administration already has entered into agreements with some large chains to do that. — Using the Defense Production Act ...
- States look for more Covid-19 vaccine doses as the nation's death toll nears 400,000on January 17, 2021 at 5:40 pm
States are racing to get Covid-19 vaccine supplies and distribution in order as the US Centers for Disease Control and Prevention warned Friday of more contagious variants of coronavirus potentially ...
- Brazil clears emergency use of Sinovac, AstraZeneca vaccines, shots beginon January 17, 2021 at 5:28 pm
(Graphic: tmsnrt.rs/34pvUyi) Delays with vaccine shipments and testing results have held ... Butantan, which is set up to fill and finish CoronaVac doses on its production line, plans to supply 46 ...
- Biden to use Defense Production Act to 'maximize' making virus vaccineson January 17, 2021 at 9:08 am
On Friday, Biden pledged to maximize the available supply of vaccines and materials needed to administer them, using a Cold War-era law called the Defense Production Act to direct private ...
- Federal Deal To Increase Vaccine Production Could Give Some Employees Early Accesson January 17, 2021 at 9:01 am
A federal manufacturing contract to increase COVID-19 vaccine production has an unusual clause that could move a company's employees and their families to the front of the vaccination line.
- Biden to use Defense Production Act to 'maximize' vaccine productionon January 17, 2021 at 4:13 am
President-elect Joe Biden says he'll use the Cold War-era law for his goal of administering 100 million COVID-19 vaccines by his 100th day in office.
- Experts: Boosting vaccine production could take weekson January 16, 2021 at 4:05 pm
President-elect Joe Biden’s vaccine distribution plan includes using the Defense Production Act to churn out supply. Experts say it could take weeks to boost production.
- Biden to use Defense Production Act for vaccine distributionon January 16, 2021 at 5:06 am
President-elect Joe Biden is pushing ahead with plans to activate the Defense Production Act and ramp up the national supply of COVID-19 vaccines the moment he takes office next week. CBS News senior ...
- Pfizer temporarily reduces European deliveries of vaccineon January 15, 2021 at 5:00 pm
U.S. pharmaceutical company Pfizer confirmed Friday it will temporarily reduce deliveries to Europe of its COVID-19 vaccine while it upgrades production capacity to ...
via Bing News